Meta AnalysisID 6187
荷丹片治疗高脂血症的临床疗效与安全性：Meta分析与系统评价
CRD42019145375
To evaluate the efficacy and safety of Hedan Tablet in patients with hyperlipidemia
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6187
- Evidence Id
- 14745
- Core Evidence Id
- 14745
- Source Meta Analysis Id
- 6166
- Herb2 Meta Analysis Id
- HBMA006166
- Crd Id
- CRD42019145375
- Title
- Clinical efficacy and safety of hedan tablets for the treatment of hyperlipidemia: a meta-analysis and systematic review
- Review Question
- To evaluate the efficacy and safety of Hedan Tablet in patients with hyperlipidemia
- Study Type Included
- Randomized controlled trials
- Condition Being Studied
- Hyperlipidemia is a major risk factor for cardiovascular and cerebrovascular diseases. Hyperlipidemia could induce atherosclerosis, leading to coronary heart disease, stroke, and myocardial infarction, increasing the incidence and mortality rate of cardio-cerebrovascular diseases.
- Participant
- Participants, adult patients (18 years of age and older) with HL whose blood lipids are abnormal for 2 consecutive tests after stopping lipid regulating agent and diet therapy 2 to 4 weeks later will be included. HL should be confirmed according to the standard diagnostic criteria including the “Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (2016). <h1>Intervention(s), exposure(s)
- Animal
- Human Disease Modelled
- Intervention
- The therapy used Hedan tablet by oral administration. The interventions used in the control group include placebo, blank control, and conventional western medicine (such as stains). The administration time for both the control and experimental groups must not be less than 4 weeks.
- Comparator Control
- Control group: placebo, blank control, and conventional western medicine (such as stains).
- Main Outcome
- The primary outcome indicators are determined according to the Guiding Principles for Clinical Research of Drugs
- Outcome Measure
- Additional Outcome
- The secondary outcome includes Serum TC, TG, LDL-C, HDL-C, apolipoprotein A (apo A), apo B
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Drugs, Chinese Herbal; Humans; Hyperlipidemias; Tablets; Treatment Outcome; hedan
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- First Submission Date
- Registration Date
- 2019-10-31
- Anticipated Start Date
- 2019-07-20
- Anticipated Completion Date
- 2020-07-01
- Title Cn
- 荷丹片治疗高脂血症的临床疗效与安全性：Meta分析与系统评价
- Title En
- Clinical efficacy and safety of hedan tablets for the treatment of hyperlipidemia: a meta-analysis and systematic review
- Bilingual Status
- complete